RecruitingNCT07683104
24
studies recruiting now
as of 7 Sept 2026
132
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
6 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT00001539
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
RecruitingNCT00028080
Evaluation, Treatment, and Follow-up of Patients With Lyme Disease
RecruitingNCT06397794
Navigating Pregnancy and Parenthood With Lyme Disease
RecruitingNCT06026969
Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 24 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Lyme disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Lyme disease
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 approved treatment and 4 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Demeclocycline
Phase 3Ceftriaxone
Phase 3Doxycycline (Doxirobe)
Phase 2Tetracycline (Achromycin v)
Phase 1Psilocybin
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).